3:58 PM
 | 
Dec 07, 2017
 |  BC Extra  |  Company News

bluebird, TC BioPharm in gamma delta CAR T deal

bluebird bio Inc. (NASDAQ:BLUE) and TC BioPharm Ltd. (Edinburgh, U.K.) partnered to discover and develop gamma delta chimeric antigen receptor (CAR) T cells to treat hematologic malignancies and solid tumors using TC BioPharm's ImmuniCAR technology.

TC BioPharm Founder and CEO Michael Leek said the partnership will initially target CD33 to treat acute myelogenous leukemia (AML).

The companies will also advance TC BioPharm's lead gamma delta...

Read the full 307 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >